

34 FGF2-G3 produced under optimized conditions was purified and tested for bioactivity on
35 *Anguilla japonica* pre-adipocytic cells, Aj1C-2x.

36 **Results and Discussion:** We have generated a recombinant *L. lactis* strain and an optimal
37 expression strategy to enable the production of secreted bioactive growth factors. Our results
38 demonstrate that this system can produce FGF2 which were able to promote the proliferation
39 of fish *Anguilla japonica* preadipocytic cells. Despite minimal purification beyond affinity
40 purification and buffer exchange, we were able to obtain comparable specific activity to
41 commercial FGF2. The final yields can be derived at 1.97 mg/L and through simple protein
42 purification and buffer exchange. Finally, this study highlights the potential use of *L. lactis*
43 secretion as an endotoxin-free alternative, compared to *E. coli*, for production of growth factors
44 for use in cultivated meat production.

45

46 Introduction

47 Cultivated meat, also known as cultured meat, has gained significant interest in recent years
48 due to global movement towards achieving sustainability development goals. It provides a
49 prospective alternative meat source to support demand from increasing population, reduce
50 environmental impact from animal agriculture and avoids animal-borne diseases (Campbell et
51 al., 2017; Godfray et al., 2018; Lynch & Pierrehumbert, 2019; Stephens et al., 2018). Cultivated
52 meat is produced through *in vitro* culturing of animal cells in cell culture media. However,
53 foetal bovine serum (FBS), a typical ingredient found in culture media, is derived from
54 extracting blood serum of bovine foetuses from animal slaughter houses (Jochems et al., 2002;
55 Kadim et al., 2015; Lee et al., 2022; Post et al., 2020; Reiss et al., 2021). This conflicts with
56 the concept of producing meat via an animal-free approach. Thus, serum-free media
57 formulations that are capable of sustaining cell culture were developed (Badenes et al., 2016;
58 Das et al., 2009; Messmer et al., 2022; Skrivergaard et al., 2023; Stout et al., 2022).
59 Subsequently, supplementation of growth factors, such as fibroblast growth factors or insulin-
60 like growth factors, into serum-free media formulations are essential to mimic proliferative and
61 developmental effects of FBS (Park et al., 2013; Santos et al., 2023; Venkatesan et al., 2022;
62 Yu et al., 2023).

63 One such growth factor of interest is the basic fibroblast growth factor, also known as fibroblast
64 growth factor 2 (FGF2), which is a member of the cytokine family. It acts by binding to cell
65 surface receptors (FGFR), activating mitogenic pathways such as PI3k/Akt pathway,
66 MAPK/ERK pathway and JNK pathway. Activation of these pathways regulates cellular
67 responses such as growth, proliferation, migration, maintenance and differentiation (Ahmad et
68 al., 2023; Bikfalvi et al., 1997; Yun et al., 2010). Production of recombinant growth factors,
69 including FGF2, for supplementation into serum-free media are most frequently done in
70 prokaryotic expression system using *Escherichia coli*. However, the recombinant proteins are
71 produced intracellularly and has high tendency for inclusion bodies formation, which
72 subsequently involve expensive and tedious downstream protein refolding and purification
73 processes. Furthermore, host-cell derived impurities, in particular endotoxins, poses health
74 risks to humans (Baneyx & Mujacic, 2004; Kaur et al., 2018; Petsch & Anspach, 2000; Sahdev
75 et al., 2008; Thomas & Baneyx, 1996). This calls for an alternative endotoxin free expression
76 system that is also economical for production of recombinant proteins.

77 *Lactococcus lactis*, a Gram-positive lactic acid bacterium that is widely used in food and
78 therapeutic applications (Bahey-El-Din et al., 2010; Kumari et al., 2011; Song et al., 2017),

79 presents a good alternative host for recombinant protein expression. The key feature of using
80 *L. lactis* expression system is its ability to secrete recombinant proteins into culture medium,
81 minimising the need for cell lysis, complex protein purification and refolding. Moreover, *L.*
82 *lactis* does not produce lipopolysaccharides and has few extracellular proteases, that causes
83 endotoxin toxicity and proteolytic degradation respectively (Frelet-Barrand, 2022; Garcia-
84 Fruitos, 2012; Morello et al., 2008). As *L. lactis* are microaerophilic, they only require a simple
85 static fermentation process without aeration, this makes possible for a simple and direct scale-
86 up to industrial scale. Among the various *L. lactis* expression systems developed, the most
87 widely used is the nisin-controlled gene expression (NICE) system, consisting of a nisRK
88 regulatory gene integrated into bacterial host chromosome and an expression vector with nisA
89 promoter to tightly regulate gene expression (de Ruyter et al., 1996; Mierau & Kleerebezem,
90 2005; Mierau, Leij, et al., 2005; Zhou et al., 2006). *L. lactis* expression system has been applied
91 for production of several growth factor proteins (Cao et al., 2020; Gao et al., 2012; Huynh &
92 Li, 2015; Zhou et al., 2021). In our lab, we have recently reported on valorisation of mammalian
93 spent culture media waste to support intracellular FGF2 production in bioreactors (Rizal et al.,
94 2024). However, comprehensive research regarding the production and secretion of functional
95 FGF2 from *L. lactis* is not available. Hence, we set forth herein to investigate the possibility of
96 employing *L. lactis* NICE expression system to produce and secrete biologically active FGF2.
97 To enhance the secretion efficiency, we fused USP45 secretory peptide and secretion
98 propeptide 1 (PP1) (Lim et al., 2017) to a thermostable FGF2 variant, FGF2-G3 (Dvorak et al.,
99 2018). Together with optimisation of media formulation and culture conditions, we were able
100 to obtain ~2 mg/L of secreted FGF2-G3. Furthermore, FGF2-G3 purified from the medium
101 was able to stimulate proliferation of the Japanese eel *Anguilla japonica* pre-adipocytic cells,
102 comparable to commercial FGF2. Together, these results signal the potential application of *L.*
103 *lactis* protein secretion system as an alternative strategy for recombinant FGF2 and potentially
104 other growth factor production to circumvent issues faced with *E. coli* for cultured meat
105 development.

106

107 **Materials and Methods**

108 **Bacterial strain, plasmid and cloning of FGF2-G3 gene**

109 *L. lactis* NZ9000 and pNZ8148 plasmid (BoCa Scientific, USA) were used for cloning and
110 expression studies. Sequence of the thermostable human FGF2-G3 was obtained from Dvorak
111 et al. (2018). To enhance expression and secretion into medium, USP45 secretion peptide
112 (Accession ABY84357) and propeptide 1 (PP1) (Lim et al., 2017) were fused at the *N*-terminus
113 of FGF2-G3 sequence. For ease of purification with Ni-NTA affinity chromatography and
114 Western blot detection, we have also included His₆ sequence at the *N*-terminus. The nucleotide
115 sequences corresponding to the amino acids were codon optimized and synthesized by IDT
116 (Singapore) for expression in *L. lactis*. The coding sequence was cloned into the multiple
117 cloning site (MCS) of pNZ8148 vector using NeBuilder HiFi Assembly (New England Biolabs,
118 USA) (Fusion protein sequence available in supplementary Figure S1), transformed into *L.*
119 *lactis* NZ9000 and plated onto M17 agar plate containing 0.5 % (w/v) glucose and 10 µg/mL
120 chloramphenicol to screen for positive recombinant clones. The positive recombinant clones
121 were further sequenced to ensure no mutations prior to protein expression with *L. lactis*
122 NZ9000.

123 **Culture optimization for FGF2-G3 expression and secretion in *L. lactis***

124 Productivity of FGF2-G3 production in *L. lactis* was assessed with varying M17 media and
125 glucose concentration. They were expressed in either M17 (supplemented with 0.5 % (w/v)
126 glucose), 2xM17 (supplemented with 0.5 % (w/v) glucose) or 2xM17 (supplemented with 2 %
127 (w/v) glucose). All cultures were also supplemented with 10 µg/mL chloramphenicol for
128 selection and maintenance of cells containing pNZ8148-FGF2-G3 plasmids. To increase
129 production and secretion level, FGF2-G3 expression was further optimized with different nisin
130 inducer concentrations (10, 25, 50 ng/mL), induction time points (OD_{600nm} 0.5, 1.0, 2.0),
131 incubation temperatures (20, 25, 30, 35 °C) and expression duration (4, 20 hours post-
132 induction). These parameters were investigated individually in 10 mL culture volume. The
133 cultures were harvested by centrifugation at 3845 g, 4 °C for 20 minutes with Sorvall ST 40
134 centrifuge (Thermo Fisher Scientific, USA). The media fraction was aspirated and concentrated
135 with a 10 kDa MWCO centrifugal filter (Merck Millipore, Ireland) to obtain secreted protein
136 fraction, while the cell pellet was resuspended in PBS, incubated at 37 °C for 1 hour with 1
137 mg/mL lysozyme and 0.05 U/µL mutanolysin and then lysed via sonication. The cell lysate
138 was centrifuged, supernatant collected as intracellular soluble fraction, and the lysed cell pellet
139 resuspended in 6M urea to obtain intracellular insoluble fraction. All 3 fractions (secreted,
140 soluble, insoluble) were analysed on SDS-PAGE to determine productivity level.

141 **Optimized production of secreted FGF2-G3**

142 A larger production volume of FGF2-G3 was performed under optimized conditions. 250 mL
143 of 2xM17 (supplemented with 2 % (w/v) glucose and chloramphenicol 10 µg/mL) was
144 inoculated with pre-culture and incubated at 30 °C until it reaches OD_{600nm} 1.0. Nisin was then
145 added to final concentration of 25 ng/mL to induce expression of FGF2-G3, and induction was
146 done at 35 °C for 20 hours. The culture was centrifuged and the media fraction containing
147 secreted FGF2-G3 was collected and purified via affinity chromatography.

148 **Purification of FGF2-G3**

149 Media fraction containing secreted FGF2-G3 was concentrated, and buffer exchanged to buffer
150 A (50 mM NaH₂PO₄, 300 mM NaCl, 10 mM Imidazole, pH 8) using crossflow filtration
151 system. The concentrated sample was loaded onto Ni-NTA Agarose (Qiagen, USA) column
152 and incubated for 60 minutes. The column was first washed with 10 mM imidazole, next with
153 20 mM imidazole, and finally eluted with 250 mM imidazole. The eluted fraction was buffer
154 exchanged to PBS for protein evaluation with SDS-PAGE and bioactivity assay. The purified
155 FGF2-G3 was quantified using Bradford method, with BSA as standard.

156 **Western Blot and SDS-PAGE**

157 An equal amount of protein from each fraction were run on NuPage 4-12 % Bis-Tris SDS-
158 PAGE gel (Thermo Fisher Scientific, USA) and transferred onto nitrocellulose membrane
159 using a Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad, USA). The
160 membrane was subsequently probed with His-Tag Antibody HRP Conjugate (Merck Millipore,
161 USA) and detected with Clarity Western ECL Blotting Substrate (Bio-Rad, USA). Expression
162 level of FGF2-G3 was determined by densitometric analysis of digital images using ImageJ
163 software (National Institute of Health, USA).

164 To analyse purity of the large-scale purified media fraction eluted from Ni-NTA agarose
165 column, 2 µg of protein was run on NuPage 4-12 % Bis-Tris SDS-PAGE gel (Thermo Fisher
166 Scientific, USA) and stained with InstantBlue Coomassie Protein stain (Abcam, UK).

167 **Bioactivity assay of FGF2-G3**

168 Biological activity of the purified FGF2-G3 was assessed using *Anguilla japonica* (Japanese
169 eel) pre-adipocytic cells, Aj1C-2x (Sugii et al., 2011). The cells were cultured in Dulbecco's
170 modified Eagle's medium (DMEM)/F12 media (Thermo Fisher Scientific, USA)
171 supplemented with reduced fetal bovine serum (2.5 %) and 10 ng/mL of FGF2 at 27 °C with
172 5 % CO₂ in a humidified incubator. Cell density and viability were determined using Vi-CELL
173 XR Cell Viability Analyzer (Beckman Coulter, USA), according to manufacturer's
174 instructions. Each well contains fresh DMEM/F12 medium supplemented with 2.5 % FBS and
175 varying concentrations of purified recombinant FGF2-G3 or positive control. Commercial heat
176 stable FGF2 (PHG0368, Thermo Fisher Scientific) was used as positive control. Aj1C-2x cells
177 were seeded into 96-well plates at seeding density of 2×10^4 cells/well. After culturing for 3
178 days, cell viability was determined with CyQuant XTT cell viability assay (X12223, Thermo
179 Fischer Scientific), according to manufacturer's instructions. The absorbance reading of the
180 media control was subtracted from the absorbance reading of each sample to determine the
181 specific absorbance reading for each sample. Subsequently, the specific absorbance reading of
182 each sample were normalized against the specific absorbance reading of the cells cultivated in
183 basal media with 2.5% FBS (0 ng/mL FGF2) for Aj1C-2x cells to calculate relative absorbance
184 fold changes. Cellular health was examined through inverted microscope under 4X
185 magnification (Nikon eclipse Ti with NIS-Elements AR 4.30.02 software, Nikon).

186 Biological activity of the purified FGF2-G3 was also further evaluated in a 6-well plate format.
187 Aj1C-2x cells were seeded at a seeding density of 3×10^5 cells/well in a 6-well plate using
188 DMEM/F12 medium (Thermo Fisher Scientific, USA) supplemented with 2.5 % FBS and
189 varying concentrations of purified recombinant FGF2-G3 or commercial heat-stable FGF2
190 (PHG0368, Thermo Fisher Scientific). After 4 days of culture, cellular health was examined
191 through inverted microscope (Nikon eclipse Ti with NIS-Elements AR 4.30.02 software,
192 Nikon). Subsequently, cells were dissociated using TrypLE™ Express Enzyme (Thermo
193 Fisher Scientific, USA) and viable cell density were measured using a Vi-CELL XR Cell
194 Viability Analyzer (Beckman Coulter, USA), following the manufacturer's protocol.

195

196 **Results and Discussion**

197 **An enhancer propeptide to enhance secretion**

198 To determine whether FGF-2 can be expressed and secreted out of *L. lactis*, we constructed an
199 expression plasmid containing FGF2-G3, a modified and stable version that has nine amino
200 acid mutations (Dvorak et al., 2018), with *N*-terminal fused to USP45 signal peptide. Our initial
201 attempts to express the fusion protein resulted in low intracellular soluble yield and no protein
202 was secreted. In previous study conducted by Lim et al. (2017), it was reported that addition of
203 a short secretion propeptide 1 (PP1) to a USP45 fusion protein could significantly enhance
204 protein secretion efficiency. Hence, we added PP1 between USP45 and FGF2-G3 as shown in
205 Figure 1a.

206 *L. lactis* cells containing the two different recombinant plasmids (with and without PP1) were
207 cultured in M17 media, supplemented with 0.5 % glucose, and expression was induced at
208 OD_{600nm} 0.5 with nisin at final concentration of 10 ng/mL. FGF2-G3 was allowed to be
209 expressed for 4 hours at 30 °C. The expression and secretion were assessed by Western blot.
210 Appearance of bands corresponding to two different fusion FGF2-G3 constructs (with and

211 without PP1) were observed. It was noted that addition of PP1 not only facilitates secretion of
212 the fusion protein, but also increases the soluble yield (Figure 1b).

213 **Optimisation of cultivation parameters**

214 Next, optimization of culture and expression conditions were examined to increase protein
215 secretion yield. Optimization of culture conditions began with expressing FGF2-G3 in varying
216 M17 and glucose concentrations (M17 + 0.5 % (w/v) glucose, 2xM17 + 0.5 % (w/v) glucose,
217 2xM17 + 2 % (w/v) glucose). 2xM17 + 2 % (w/v) glucose medium proved to be the best for
218 secretion of FGF2-G3 (Figure 2a).

219 Doubling the amount of M17 increased the soluble protein fractions. Looking at the growth
220 curve of cells grown in different medias (Figure 2b), we hypothesize that doubling M17 not
221 only provides additional nitrogen-based nutrients to support cell metabolism for a higher cell
222 density culture, but also increases the buffering capacity against lactic acid produced during
223 fermentation, due to increased amount of Disodium- β -glycerophosphate, a buffering agent
224 found in M17 medium composition (Hayek et al., 2019; Terzaghi & Sandine, 1975; Zhang
225 et al., 2009). These then worked in concert with increased glucose concentration, permitting
226 *L. lactis* to extend its growth phase for higher FGF2-G3 production and, in particular, secretion
227 titer. Further culture optimizations were performed using 2xM17 + 2 % (w/v) glucose medium.

228 FGF2-G3 production also improved when the culture was induced at a higher cell density of
229 OD_{600nm} 1.0 (Figure 2c). This is anticipated since higher cell density would also mean more
230 plasmids available for induction, which in-turn raises protein expression titer. With the increase
231 in cell density, more nisin may be needed for complete induction and thus we proceeded to
232 determine new optimal nisin concentration. Culture induction was performed when cells
233 reached OD_{600nm} 1.0 with nisin at final concentrations of 10, 25 or 50 ng/mL. The expression
234 level of FGF2-G3 increased when nisin concentration was up from 10 to 25 ng/mL (Figure 2c),
235 indicating correlation between cell density and nisin concentration needed for maximal
236 induction. There was no further increase in expression level with 50 ng/mL nisin. Induction
237 was also tested at OD_{600nm} 2.0, but it did not lead to higher FGF2-G3 yield.

238 As the FGF2-G3 used in this study has been engineered for stability, we predicted that
239 translation and folding within *L. lactis* is not limiting, rather the rate of translation/transcription
240 can be further improved via fermentation optimisation. Temperature and expression duration
241 are two important post-induction conditions for optimization as they balance between bacterial
242 growth, functional protein yield and protein degradation. It has been suggested that lower
243 temperature improves proper protein folding and solubility (Mierau, Olieman, et al., 2005;
244 Sahdev et al., 2008; Yu et al., 2021), and prolonged expression should also be avoided as it
245 leads to higher tendency for protein degradation caused by protein instability, lactate
246 accumulation that disrupts energy metabolism for protein expression and/or triggering of cell
247 stress response (Zhou et al., 2006). Interestingly, results for the present study showed an
248 increase in secreted protein yield along with increasing temperature and expression duration,
249 with 35 °C and 20 hour being the optimal temperature and harvest time-point (Figure 2d).

250 The highest expression and secretion of FGF2-G3 was achieved when cells were cultured in
251 2xM17 medium supplemented with 2 % (w/v) glucose and induced at OD_{600nm} 1.0 with 25
252 ng/ml nisin for 20 hours at 35 °C. The culture was scaled up from 10 mL to 250 mL for
253 subsequent purification and bioactivity testing. The secreted fraction of the overexpressed
254 FGF2-G3 was purified using immobilized metal affinity chromatography, which utilized Ni-
255 NTA resin matrix, and the identity and purity were determined with Western blot and

256 Coomassie staining (Figure 3a and 3b). The purified yield achieved herein is about 1.97 mg for
257 1 L of fermentation media, which is comparable to previous study by Rizal et al. (2014) where
258 2.6 mg/L of intracellular FGF2-G3 was produced from bioreactor fermentation. Based on an
259 estimated requirement of 50 ng/mL recombinant FGF2-G3 in cultivated meat culture, secreted
260 growth factors produced from 1 L fermentation provides enough growth factors for 39.4 L of
261 cultivated meat culture. Secretion titers could be further raised with i) plasmid modifications,
262 such as replacing promoters, ii) increasing membrane porosity by addition of chemicals, such
263 as peptides and detergents, into culture media and iii) using bioreactor fermentation with
264 controlled environment.

265 **Biological activity assessment of the purified FGF2**

266 To assess the biological activity of the purified FGF2-G3, growth stimulation on *Anguilla*
267 *japonica* (Japanese eel) pre-adipocytic cells, Aj1C-2x, was measured using XTT assay and
268 compared against a commercial heat stable FGF2 (positive control). As shown in Figure 3c, an
269 increase in metabolic activity was detected when cells were cultured with the purified FGF2-
270 G3, indicating its ability to promote cell proliferation and exhibited comparable bioactivity
271 profile to the commercial FGF2. This is further supported by an increase in cell density
272 observed through microscopy and cell count using a cell viability analyzer (Figure 3d and 3e).
273 The positive result suggests that our secreted FGF2-G3 can be used to stimulate fish stem cells
274 for cultivated fish meat and cultivating adipocytes (fats) for enhancement of meat texture and
275 flavour. Future bioactivity testing can be performed on mammalian cell lines, such as bovine,
276 porcine and chicken muscle cells, to widen its application range in cultivated meat.

277

278 **Conclusion**

279 In summary, this study demonstrated that functional FGF2 can be expressed and secreted using
280 the *L. lactis* expression system. We employed a multi-modal optimization strategy that
281 included a secretion-enhancing propeptide and further cultivation optimizations. Specifically,
282 we utilized a nutrient-rich 2xM17 medium containing 2% (w/v) glucose. The ability of the *L.*
283 *lactis*-produced FGF2-G3 to stimulate growth of Japanese eel cells suggests that *L. lactis* could
284 be used as a safer alternative for production of growth factors for cultured meat development.
285 The secretion of recombinant proteins into culture medium by *L. lactis* simplifies the
286 production process and presents opportunities to lower production cost for cultured meat.
287 Future efforts could be directed at expressing other growth factors, such as EGF, IGF and
288 TGF β 1, in *L. lactis* and scaling-up in bioreactors for precision fermentation of recombinant
289 growth factors.

290

291 **Abbreviations**

292 EGF: Epidermal Growth Factor; FBS: Foetal Bovine Serum; FGF2: Fibroblast Growth Factor
293 2; GRAS: Generally Recognized As Safe; IGF: Insulin-like Growth Factor; NICE: Nisin
294 Controlled Gene Expression System; TGF- β 1: Transforming Growth Factor β 1

295

296

297 **Author Contributions**

298 PH: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology,
299 Validation, Visualization, Writing – Original draft, Project administration. YC: Formal
300 Analysis, Investigation, Methodology, Validation, Writing – Review and editing. JQ: Formal
301 Analysis, Validation, Writing – Review and editing. SN: Writing – Review and editing. FW:
302 Writing – Review and editing. DO: Conceptualization, Funding acquisition, Project
303 administration, Supervision, Writing – Review and editing.

304

305 **Funding**

306 The author(s) declare that financial support was received for the research and/or publication of
307 this article. This research was supported by the Agency for Science, Technology and Research
308 (A-STAR), Singapore, and was funded by Singapore Food Story (SFS) R&D Programme
309 (H20H8a0003, W23W2D0009 and NRF-SFSRND2FF-0003).

310

311 **Conflict of Interest**

312 The authors declare that the research was conducted in the absence of any commercial or
313 financial relationships that could be construed as a potential conflict of interest.

314


315 **Acknowledgments**

316 We would like to thank Shigeki Sugii and Lamony Chew for providing us with the *Anguilla*
317 *japonica* pre-adipocytic cell lines and Zarra Iwana Huang for her assistance in culturing work.

318

319 **Figures and Figure Captions**


320



321

322 **Figure 1. Expression vector constructs.** (A) Schematic representation of expression vectors.
 323 FGF2-G3 with *N*-terminal fusion of signalling-secretion peptides (USP45 with and without
 324 PP1) and His₆-tag in pNZ8148 vector. Protein sequence and insertion site available in
 325 supplementary file: Figure S1 (B) Western Blot of FGF2-G3 expression and secretion with and
 326 without propeptide (PP1) sequence in fusion plasmid.


327



328

329 **Figure 2. Expression of FGF2-G3 under different culture parameters.** (A) Western blot of
 330 secreted, soluble and insoluble fraction of cell lysate. Cells were grown and induced in different
 331 media concentrations (A: M17 + 0.5 % (w/v) glucose, B: 2xM17 + 0.5 % (w/v) glucose, C:
 332 2xM17 + 2 % (w/v) glucose); (B) Growth curve of un-induced cells grown in different media
 333 formulations (A-: M17 + 0.5 % (w/v) glucose, B-: 2xM17 + 0.5 % (w/v) glucose, C-: 2xM17
 334 + 2 % (w/v) glucose) (C) Densitometry analysis of protein secretion yield under different
 335 induction OD (OD_{600nm} 0.5, 1.0, 2.0) and nisin concentration (10, 25 or 50 ng/mL); (D) Western
 336 blot of secreted protein with post-induction temperature and expression duration at 20, 25, 30
 337 or 35 °C and 4 or 20 hrs, respectively.

338




339

340 **Figure 3. Purification and Effect of FGF2-G3 on proliferation of *Anguilla japonica* cells,**
 341 **Aj1C-2x. (A)** Western blot analysis of purified FGF2-G3; **(B)** Coomassie stain of purified
 342 FGF2-G3; **(C)** XTT assay to determine cell proliferation effect of varying concentrations of
 343 commercial FGF2 and purified recombinant FGF2-G3 on Aj1C-2x cells. Absorbance
 344 readings were normalized to cells grown in medium without FGF2. Data plotted as average
 345 absorbance with error bars representing SD calculated for biological and technical triplicates.
 346 T-test analysis indicates no significant differences between commercial and recombinant
 347 FGF2 ($P > 0.05$); **(D)** Representative images of *Anguilla japonica* cells, Aj1C-2x, observed
 348 under 4x magnification, grown in fresh DMEM/F12 medium supplemented with 2.5 % FBS
 349 with varying concentrations of purified recombinant FGF2-G3; **(E)** Total cell number
 350 measured after 4 days of culture using Vi-CELL XR Cell Viability Analyzer. Data are
 351 presented as total cell counts, with error bars representing the standard deviation from
 352 biological duplicates.

353

354



356

357 **Figure S1.** Protein sequence of fusion FGF2-G3 construct.

358

359 **References**

360 Ahmad, S. S., Chun, H. J., Ahmad, K., Shaikh, S., Lim, J. H., Ali, S., Han, S. S., Hur, S. J., Sohn, J. H., Lee,
 361 E. J., & Choi, I. (2023). The roles of growth factors and hormones in the regulation of muscle
 362 satellite cells for cultured meat production. *J Anim Sci Technol*, *65*(1), 16-31.
 363 <https://doi.org/10.5187/jast.2022.e114>

364 Badenes, S. M., Fernandes, T. G., Cordeiro, C. S., Boucher, S., Kuninger, D., Vemuri, M. C., Diogo, M.
 365 M., & Cabral, J. M. (2016). Defined Essential 8 Medium and Vitronectin Efficiently Support
 366 Scalable Xeno-Free Expansion of Human Induced Pluripotent Stem Cells in Stirred
 367 Microcarrier Culture Systems. *PLoS One*, *11*(3), e0151264.
 368 <https://doi.org/10.1371/journal.pone.0151264>

369 Bahey-El-Din, M., Gahan, C. G., & Griffin, B. T. (2010). Lactococcus lactis as a cell factory for delivery
 370 of therapeutic proteins. *Curr Gene Ther*, *10*(1), 34-45.
 371 <https://doi.org/10.2174/156652310790945557>

372 Baneyx, F., & Mujacic, M. (2004). Recombinant protein folding and misfolding in Escherichia coli. *Nat*
 373 *Biotechnol*, *22*(11), 1399-1408. <https://doi.org/10.1038/nbt1029>

374 Bikfalvi, A., Klein, S., Pintucci, G., & Rifkin, D. B. (1997). Biological roles of fibroblast growth factor-2.
 375 *Endocr Rev*, *18*(1), 26-45. <https://doi.org/10.1210/edrv.18.1.0292>

376 Campbell, B. M., Beare, D. J., Bennett, E. M., Hall-Spencer, J. M., Ingram, J. S. I., Jaramillo, F., Ortiz, R.,
 377 Ramankutty, N., Sayer, J. A., & Shindell, D. (2017). Agriculture production as a major driver of

378 the Earth system exceeding planetary boundaries. *Ecology and Society*, 22(4).
379 <https://www.jstor.org/stable/26798991>

380 Cao, W. Y., Dong, M., Hu, Z. Y., Wu, J., Li, Y. C., & Xu, H. D. (2020). Recombinant *Lactococcus lactis*
381 NZ3900 expressing bioactive human FGF21 reduced body weight of Db/Db mice through the
382 activity of brown adipose tissue. *Benef Microbes*, 11(1), 67-78.
383 <https://doi.org/10.3920/BM2019.0093>

384 Das, M., Rumsey, J. W., Bhargava, N., Gregory, C., Reidel, L., Kang, J. F., & Hickman, J. J. (2009).
385 Developing a novel serum-free cell culture model of skeletal muscle differentiation by
386 systematically studying the role of different growth factors in myotube formation. *In Vitro*
387 *Cell Dev Biol Anim*, 45(7), 378-387. <https://doi.org/10.1007/s11626-009-9192-7>

388 de Ruyter, P. G., Kuipers, O. P., & de Vos, W. M. (1996). Controlled gene expression systems for
389 *Lactococcus lactis* with the food-grade inducer nisin. *Appl Environ Microbiol*, 62(10), 3662-
390 3667. <https://doi.org/10.1128/aem.62.10.3662-3667.1996>

391 Dvorak, P., Bednar, D., Vanacek, P., Balek, L., Eiselleova, L., Stepankova, V., Sebestova, E., Kunova
392 Bosakova, M., Konecna, Z., Mazurenko, S., Kunka, A., Vanova, T., Zoufalova, K., Chaloupkova,
393 R., Brezovsky, J., Krejci, P., Prokop, Z., Dvorak, P., & Damborsky, J. (2018). Computer-assisted
394 engineering of hyperstable fibroblast growth factor 2. *Biotechnol Bioeng*, 115(4), 850-862.
395 <https://doi.org/10.1002/bit.26531>

396 Frelet-Barrand, A. (2022). *Lactococcus lactis*, an Attractive Cell Factory for the Expression of
397 Functional Membrane Proteins. *Biomolecules*, 12(2). <https://doi.org/10.3390/biom12020180>

398 Gao, G., Qiao, J. J., Yang, C. H., Jiang, D. Z., Li, R. Q., Su, J. J., Xu, H. J., Zhang, X. M., Bai, Y. L., & Qiao,
399 M. Q. (2012). Functional expression of mouse insulin-like growth factor-I with food-grade
400 vector in *Lactococcus lactis* NZ9000. *Lett Appl Microbiol*, 54(5), 404-409.
401 <https://doi.org/10.1111/j.1472-765X.2012.03222.x>

402 Garcia-Fruitos, E. (2012). Lactic Acid Bacteria: a promising alternative for recombinant protein
403 production. *Microb Cell Fact*, 11, 157. <https://doi.org/10.1186/1475-2859-11-157>

404 Godfray, H. C. J., Aveyard, P., Garnett, T., Hall, J. W., Key, T. J., Lorimer, J., Pierrehumbert, R. T.,
405 Scarborough, P., Springmann, M., & Jebb, S. A. (2018). Meat consumption, health, and the
406 environment. *Science*, 361(6399). <https://doi.org/10.1126/science.aam5324>

407 Hayek, S. A., Gyawali, R., Aljaloud, S. O., Krastanov, A., & Ibrahim, S. A. (2019). Cultivation media for
408 lactic acid bacteria used in dairy products. *J Dairy Res*, 86(4), 490-502.
409 <https://doi.org/10.1017/S002202991900075X>

410 Huynh, E., & Li, J. (2015). Generation of *Lactococcus lactis* capable of coexpressing epidermal growth
411 factor and trefoil factor to enhance in vitro wound healing. *Appl Microbiol Biotechnol*,
412 99(11), 4667-4677. <https://doi.org/10.1007/s00253-015-6542-0>

413 Jochems, C. E., van der Valk, J. B., Stafleu, F. R., & Baumans, V. (2002). The use of fetal bovine serum:
414 ethical or scientific problem? *Altern Lab Anim*, 30(2), 219-227.
415 <https://doi.org/10.1177/026119290203000208>

416 Kadim, I. T., Mahgoub, O., Baqir, S., Faye, B., & Purchas, R. (2015). Cultured meat from muscle stem
417 cells: A review of challenges and prospects. *Journal of Integrative Agriculture*, 14(2), 222-
418 233. [https://doi.org/https://doi.org/10.1016/S2095-3119\(14\)60881-9](https://doi.org/https://doi.org/10.1016/S2095-3119(14)60881-9)

419 Kaur, J., Kumar, A., & Kaur, J. (2018). Strategies for optimization of heterologous protein expression
420 in *E. coli*: Roadblocks and reinforcements. *Int J Biol Macromol*, 106, 803-822.
421 <https://doi.org/10.1016/j.ijbiomac.2017.08.080>

422 Kumari, A., Catanzaro, R., & Marotta, F. (2011). Clinical importance of lactic acid bacteria: a short
423 review. *Acta Biomed*, 82(3), 177-180. <https://www.ncbi.nlm.nih.gov/pubmed/22783712>

424 Lee, D. Y., Lee, S. Y., Yun, S. H., Jeong, J. W., Kim, J. H., Kim, H. W., Choi, J. S., Kim, G. D., Joo, S. T.,
425 Choi, I., & Hur, S. J. (2022). Review of the Current Research on Fetal Bovine Serum and the
426 Development of Cultured Meat. *Food Sci Anim Resour*, 42(5), 775-799.
427 <https://doi.org/10.5851/kosfa.2022.e46>

428 Lim, P. Y., Tan, L. L., Ow, D. S., & Wong, F. T. (2017). A propeptide toolbox for secretion optimization
429 of *Flavobacterium meningosepticum* endopeptidase in *Lactococcus lactis*. *Microb Cell Fact*,
430 16(1), 221. <https://doi.org/10.1186/s12934-017-0836-0>

431 Lynch, J., & Pierrehumbert, R. (2019). Climate impacts of cultured meat and beef cattle. *Front*
432 *Sustain Food Syst*, 3. <https://doi.org/10.3389/fsufs.2019.00005>

433 Messmer, T., Klevernic, I., Furquim, C., Ovchinnikova, E., Dogan, A., Cruz, H., Post, M. J., & Flack, J. E.
434 (2022). A serum-free media formulation for cultured meat production supports bovine
435 satellite cell differentiation in the absence of serum starvation. *Nat Food*, 3(1), 74-85.
436 <https://doi.org/10.1038/s43016-021-00419-1>

437 Mierau, I., & Kleerebezem, M. (2005). 10 years of the nisin-controlled gene expression system (NICE)
438 in *Lactococcus lactis*. *Appl Microbiol Biotechnol*, 68(6), 705-717.
439 <https://doi.org/10.1007/s00253-005-0107-6>

440 Mierau, I., Leij, P., van Swam, I., Blommestein, B., Floris, E., Mond, J., & Smid, E. J. (2005). Industrial-
441 scale production and purification of a heterologous protein in *Lactococcus lactis* using the
442 nisin-controlled gene expression system NICE: the case of lysostaphin. *Microb Cell Fact*, 4,
443 15. <https://doi.org/10.1186/1475-2859-4-15>

444 Mierau, I., Olieman, K., Mond, J., & Smid, E. J. (2005). Optimization of the *Lactococcus lactis* nisin-
445 controlled gene expression system NICE for industrial applications. *Microb Cell Fact*, 4, 16.
446 <https://doi.org/10.1186/1475-2859-4-16>

447 Morello, E., Bermudez-Humaran, L. G., Llull, D., Sole, V., Miraglio, N., Langella, P., & Poquet, I. (2008).
448 *Lactococcus lactis*, an efficient cell factory for recombinant protein production and
449 secretion. *J Mol Microbiol Biotechnol*, 14(1-3), 48-58. <https://doi.org/10.1159/000106082>

450 Park, Y. H., Gong, S. P., Kim, H. Y., Kim, G. A., Choi, J. H., Ahn, J. Y., & Lim, J. M. (2013). Development
451 of a serum-free defined system employing growth factors for preantral follicle culture. *Mol*
452 *Reprod Dev*, 80(9), 725-733. <https://doi.org/10.1002/mrd.22204>

453 Petsch, D., & Anspach, F. B. (2000). Endotoxin removal from protein solutions. *J Biotechnol*, 76(2-3),
454 97-119. [https://doi.org/10.1016/s0168-1656\(99\)00185-6](https://doi.org/10.1016/s0168-1656(99)00185-6)

455 Post, M. J., Levenberg, S., Kaplan, D. L., Genovese, N., Fu, J., Bryant, C. J., Negowetti, N., Verzijden, K.,
456 & Moutsatsou, P. (2020). Scientific, sustainability and regulatory challenges of cultured
457 meat. *Nature Food*, 1(7), 403-415. <https://doi.org/10.1038/s43016-020-0112-z>

458 Reiss, J., Robertson, S., & Suzuki, M. (2021). Cell Sources for Cultivated Meat: Applications and
459 Considerations throughout the Production Workflow. *Int J Mol Sci*, 22(14).
460 <https://doi.org/10.3390/ijms22147513>

461 Rizal, J., Mainali, P., Quek, J. P., Lee Ling, T., Bi, J., Chan, A. J., Gaffoor, A. A., Ming Chew, L. J., Sugii,
462 S., Ng, S. K., Ow, D. S.-W., & Wong, F. T. (2024). Valorisation of spent cultivated meat media
463 for recombinant FGF2 production in GRAS *Lactococcus lactis*. *bioRxiv*,
464 2024.2008.2001.606190. <https://doi.org/10.1101/2024.08.01.606190>

465 Sahdev, S., Khattar, S. K., & Saini, K. S. (2008). Production of active eukaryotic proteins through
466 bacterial expression systems: a review of the existing biotechnology strategies. *Mol Cell*
467 *Biochem*, 307(1-2), 249-264. <https://doi.org/10.1007/s11010-007-9603-6>

468 Santos, A. C. A., Camarena, D. E. M., Roncoli Reigado, G., Chambergo, F. S., Nunes, V. A., Trindade,
469 M. A., & Stuchi Maria-Engler, S. (2023). Tissue Engineering Challenges for Cultivated Meat to
470 Meet the Real Demand of a Global Market. *Int J Mol Sci*, 24(7).
471 <https://doi.org/10.3390/ijms24076033>

472 Skrivergaard, S., Young, J. F., Sahebkhari, N., Semper, C., Venkatesan, M., Savchenko, A., Stogios,
473 P. J., Therkildsen, M., & Rasmussen, M. K. (2023). A simple and robust serum-free media for
474 the proliferation of muscle cells. *Food Res Int*, 172, 113194.
475 <https://doi.org/10.1016/j.foodres.2023.113194>

476 Song, A. A., In, L. L. A., Lim, S. H. E., & Rahim, R. A. (2017). A review on *Lactococcus lactis*: from food
477 to factory. *Microb Cell Fact*, 16(1), 55. <https://doi.org/10.1186/s12934-017-0669-x>

478 Stephens, N., Di Silvio, L., Dunsford, I., Ellis, M., Glencross, A., & Sexton, A. (2018). Bringing cultured
479 meat to market: Technical, socio-political, and regulatory challenges in cellular agriculture.
480 *Trends in Food Science & Technology*, 78, 155-166.
481 <https://doi.org/https://doi.org/10.1016/j.tifs.2018.04.010>

482 Stout, A. J., Mirliani, A. B., Rittenberg, M. L., Shub, M., White, E. C., Yuen, J. S. K., Jr., & Kaplan, D. L.
483 (2022). Simple and effective serum-free medium for sustained expansion of bovine satellite
484 cells for cell cultured meat. *Commun Biol*, 5(1), 466. [https://doi.org/10.1038/s42003-022-](https://doi.org/10.1038/s42003-022-03423-8)
485 [03423-8](https://doi.org/10.1038/s42003-022-03423-8)

486 Sugii, S., Kida, Y., Berggren, W. T., & Evans, R. M. (2011). Feeder-dependent and feeder-independent
487 iPS cell derivation from human and mouse adipose stem cells. *Nat Protoc*, 6(3), 346-358.
488 <https://doi.org/10.1038/nprot.2010.199>

489 Terzaghi, B. E., & Sandine, W. E. (1975). Improved medium for lactic streptococci and their
490 bacteriophages. *Appl Microbiol*, 29(6), 807-813. [https://doi.org/10.1128/am.29.6.807-](https://doi.org/10.1128/am.29.6.807-813.1975)
491 [813.1975](https://doi.org/10.1128/am.29.6.807-813.1975)

492 Thomas, J. G., & Baneyx, F. (1996). Protein misfolding and inclusion body formation in recombinant
493 *Escherichia coli* cells overexpressing Heat-shock proteins. *J Biol Chem*, 271(19), 11141-11147.
494 <https://doi.org/10.1074/jbc.271.19.11141>

495 Venkatesan, M., Semper, C., Skrivergaard, S., Di Leo, R., Mesa, N., Rasmussen, M. K., Young, J. F.,
496 Therkildsen, M., Stogios, P. J., & Savchenko, A. (2022). Recombinant production of growth
497 factors for application in cell culture. *iScience*, 25(10), 105054.
498 <https://doi.org/10.1016/j.isci.2022.105054>

499 Yu, B., Sun, W., Huang, Z., Sun, G., Li, L., Gu, J., Zheng, M., Li, X., Chun, C., Hui, Q., & Wang, X. (2021).
500 Large-Scale Preparation of Highly Stable Recombinant Human Acidic Fibroblast Growth
501 Factor in *Escherichia coli* BL21(DE3) plyS Strain. *Front Bioeng Biotechnol*, 9, 641505.
502 <https://doi.org/10.3389/fbioe.2021.641505>

503 Yu, I. S., Choi, J., Kim, M. K., & Kim, M. J. (2023). The Comparison of Commercial Serum-Free Media
504 for Hanwoo Satellite Cell Proliferation and the Role of Fibroblast Growth Factor 2. *Food Sci*
505 *Anim Resour*, 43(6), 1017-1030. <https://doi.org/10.5851/kosfa.2023.e68>

506 Yun, Y. R., Won, J. E., Jeon, E., Lee, S., Kang, W., Jo, H., Jang, J. H., Shin, U. S., & Kim, H. W. (2010).
507 Fibroblast growth factors: biology, function, and application for tissue regeneration. *J Tissue*
508 *Eng*, 2010, 218142. <https://doi.org/10.4061/2010/218142>

509 Zhang, G., Mills, D. A., & Block, D. E. (2009). Development of chemically defined media supporting
510 high-cell-density growth of lactococci, enterococci, and streptococci. *Appl Environ Microbiol*,
511 75(4), 1080-1087. <https://doi.org/10.1128/AEM.01416-08>

512 Zhou, X. X., Li, W. F., Ma, G. X., & Pan, Y. J. (2006). The nisin-controlled gene expression system:
513 construction, application and improvements. *Biotechnol Adv*, 24(3), 285-295.
514 <https://doi.org/10.1016/j.biotechadv.2005.11.001>

515 Zhou, Y., Chen, P., Shi, S., Li, X., Shi, D., Zhou, Z., Li, Z., & Xiao, Y. (2021). Expression of Gallus
516 Epidermal Growth Factor (gEGF) with Food-Grade *Lactococcus lactis* Expression System and
517 Its Biological Effects on Broiler Chickens. *Biomolecules*, 11(1).
518 <https://doi.org/10.3390/biom11010103>

519